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Abstract
The biguanide drug, metformin, commonly used to treat type-2 diabetes, has been shown to extend lifespan and reduce
fecundity in C. elegans through a dietary restriction-like mechanism via the AMP-activated protein kinase (AMPK) and the
AMPK-activating kinase, LKB1. We have investigated whether the longevity-promoting effects of metformin are
evolutionarily conserved using the fruit fly, Drosophila melanogaster. We show here that while feeding metformin to
adult Drosophila resulted in a robust activation of AMPK and reduced lipid stores, it did not increase lifespan in either male
or female flies. In fact, we found that when administered at high concentrations, metformin is toxic to flies. Furthermore, no
decreases in female fecundity were observed except at the most toxic dose. Analysis of intestinal physiology after
metformin treatment suggests that these deleterious effects may result from disruptions to intestinal fluid homeostasis.
Thus, metformin appears to have evolutionarily conserved effects on metabolism but not on fecundity or lifespan.
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Introduction
Dietary restriction (DR), defined as a reduction in caloric intake
that is not accompanied by malnutrition, increases lifespan in all
species tested so far including primates [1,2], making it the most
robust longevity-assurance mechanism identified to date. In
addition to its effects on lifespan, DR has also been shown to
slow the progression of age-related functional decline and delay
the onset of several age-related diseases in laboratory animals
(reviewed in [3]). Data from dietary restriction studies in humans
has revealed several metabolic benefits of DR similar to those
observed in model organisms [4,5] suggesting that DR may also be
beneficial to health and longevity in humans. Long-term DR in
humans, however, is impractical as the majority of people are
unwilling to significantly restrict their food intake over a long
period of time. Thus, pharmacological interventions that re-
capitulate the health benefits of DR without necessitating a re-
duction in food intake (so called DR-mimetics) could provide an
attractive method of improving health and well-being in older
people.
One such putative DR-mimetic is the biguanide drug,
metformin, widely prescribed as a treatment for type-2 diabetes.
Metformin has been shown to induce a similar, overlapping
transcriptional profile to both short-term and long-term DR
especially in metabolic transcripts [6] suggesting that these
interventions modulate similar downstream pathways. In support
of this, metformin induces physiological phenotypes similar to
those produced by DR. Thus, metformin lowers blood glucose,
predominantly by decreasing its production in the liver [7],
increases insulin-dependent glucose uptake in peripheral tissues
[8], lowers circulating insulin levels [9] and promotes fatty acid
metabolism [10], all physiological hallmarks of DR [3]. In
addition, metformin has been shown to delay disease progression
and improve survival in several rodent models that are prone to
cancer or other diseases [11,12,13,14,15,16,17]. Even in diabetic
human patients, metformin treatment is associated with lowered
cancer incidence and increased survival, although these effects
may be primarily mediated by increased weight loss in obese
diabetic patients [18]. However, the effects of metformin on
lifespan in a heterogeneous long-lived population are less clear and
the results from laboratory studies using rodents are confounded
by several experimental factors including the use of short-lived or
disease model strains [11,13,15], reductions in food consumption
and/or body weight in metformin-treated animals [16], absence of
metabolic phenotypes normally induced by metformin [19], lack
of a positive control within the experiment (for example, a DR
group) [17] or absence of lifespan extension in the positive control
group [19].
Recently, a comprehensive study in C. elegans has shown that
metformin increases the lifespan of wild-type worms and produces
several DR-like phenotypes in otherwise fully-fed animals, in-
cluding reduced fecundity and lowered fat stores [20]. These
effects of metformin were not additive with a genetic model of DR
in worms, the eat-2 mutation, suggesting that metformin increases
lifespan via a DR-related mechanism in worms [20].
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The molecular targets of metformin are still not well
characterised, although one candidate is the AMP-activated
protein kinase (AMPK). AMPK is a key nutrient sensor that plays
an important role in metabolism and the regulation of whole body
energy balance [21,22]. AMPK is activated by changes in the
AMP/ATP ratio and upon activation, induces catabolic pathways
to restore ATP levels by promoting glycolysis and fatty acid
oxidation as well as increasing mitochondrial biogenesis and the
metabolism of mitochondrial substrates [23]. In mammals, AMPK
and the AMPK-activating kinase, LKB1, are also activated by
metformin [21,24] and this activation is required for several of the
metabolic effects of metformin including fatty acid oxidation and
the inhibition of glucose production by liver cells [21,25]. The
mechanism by which metformin increases AMPK activity remains
unclear, although neither AMPK nor LKB1 are thought to be
direct targets of metformin. More likely, metformin activates
AMPK by increasing the amount of cytosolic AMP as metformin
inhibits complex I of the mitochondrial electron transport chain
[26] and inhibits AMP deaminase [27] thus decreasing ATP
production.
In addition to metabolic regulation, AMPK also plays an
important role in the regulation of lifespan. In Drosophila,
ubiquitous reduction of AMPK activity [28] or inhibition of
AMPK specifically in muscle is sufficient to decrease lifespan [29]
while over-expression of LKB1 also promotes longevity in flies
[30]. In C elegans, genetic deletion of the AMPK catalytic subunit,
aak-2, decreases lifespan while over-expression of aak-2 increases
lifespan [31] and several DR protocols require aak-2 to promote
DR-mediated lifespan extension [32,33]. Furthermore, both aak-2
and lkb-1 are required in worms to mediate the lifespan effects of
metformin [20]. Thus, in worms AMPK is an important mediator
of the beneficial effects of both DR and metformin.
In this study, we have examined whether the beneficial effects of
metformin treatment on the lifespan of otherwise fully fed animals
are evolutionary conserved using the fruit fly, Drosophila melanoga-
ster. We demonstrate that while oral administration of metformin
to adult flies activates the fly AMPK, this does not lead to an
increase in lifespan. In fact, we found that metformin is toxic to
flies in a dose-dependent manner. Unlike in worms, metformin
treatment in flies did not delay or reduce reproduction except at
the most toxic dose. We did, however, find that metformin reduces
fat stores in flies even at a moderate dosage. The toxicity of
metformin in flies may be mediated via perturbations in intestinal
homeostasis as flies treated with high concentrations of metformin
produce more concentrated faecal deposits indicative of intestinal
fluid imbalance. Taken together, our data suggest that metformin
treatment has overlapping effects on AMPK activation and lipid
metabolism in worms and flies but that the beneficial effects of
metformin on longevity are not conserved between these two
species.
Results
Activation of Drosophila AMPK after Ingestion of
Metformin
We first assessed the efficacy of oral administration of
metformin in Drosophila by measuring its accumulation in fly
tissues. Adult flies were fed increasing concentrations of metformin
for 7 days and fly extracts were prepared after the gut was cleared
of ingested food. We could readily detect metformin in tissue
extracts by mass spectrometric analysis even at the lowest
administered dose of 1 mM (Figure 1A). Moreover, the concen-
tration of metformin in fly tissue extracts increased with increasing
concentration in the food so with 10 mM and 100 mM metformin
in the food the concentration of metformin in fly tissue extracts
increased to 0.0460.004 nmol/mg and 0.460.05 nmol/mg, re-
spectively (Figure 1A). This is comparable to the tissue concen-
tration of metformin in mice after oral administration which is in
the range of 0.012 to 2.29 nmol/mg of tissue depending on the
tissue type [34]. Thus, metformin appears to be efficiently
absorbed from the fly gut after ingestion and accumulates in the
body tissues.
To determine if oral administration of metformin activates
AMPK in Drosophila, we measured phosphorylation of the catalytic
subunit of AMPK at Thr172 which is required for AMPK
activation. Western blot analysis of whole-fly protein extracts using
a phospho-specific antibody revealed a dose-dependent increase in
phospho-Thr172-AMPK levels after metformin treatment
(Figure 1B) confirming that oral ingestion of metformin activates
Drosophila AMPK in vivo.
Metformin Treatment does not Extend Lifespan in
Drosophila
We next investigated the effects of metformin on Drosophila
lifespan when administered at different concentrations. No effect
on survival was observed for male flies maintained on food
containing 1 mM, 2.5 mM, 5 mM, 10 mM, 25 mM or 50 mM
metformin, with a significant decrease in survival at 100 mM
metformin (Figure 2A and 2B). For female flies, again no effect on
Figure 1. Metformin treatment of adult Drosophila activates
AMPK. A. Mass spectrometric determination of metformin concentra-
tion in whole fly extracts. Female flies were sampled after 7 days of
metformin treatment at concentrations of 1, 10 and 100 mM. Before
sampling, flies were incubated in the absence of metformin for 5 hours
to allow for gut emptying. A dose-dependent increase in metformin
accumulation in fly tissues was observed. Data are represented as the
mean of three independent replicate samples 6 SEM. B. Western blot
analysis of phospho-Thr172-AMPK expression in whole-fly protein
extracts. Flies were sampled after 7 days of metformin treatment at
concentrations of 0, 5, 10, 25, 50 and 100 mM. A dose-dependent
increase in phospho-Thr172-AMPK levels was observed. Actin was used
as a loading control.
doi:10.1371/journal.pone.0047699.g001
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survival was observed at 1 mM, 2.5 mM, 5 mM or 10 mM
metformin, while increasing the concentration of metformin above
10 mM resulted in a dose-dependent decrease in lifespan
(Figure 2A and 2B). Thus, metformin treatment in Drosophila does
not appear to offer any benefits for survival and is actually toxic at
higher doses.
In C. elegans, metformin not only increases lifespan but also
causes both a reduction and delay in reproduction [20]. We
therefore examined the effects of metformin treatment on female
egg-laying. Females fed with 5 mM and 10 mM metformin did
not show any differences in egg-laying compared to untreated
control females. After 7 days of treatment, females on 25 mM and
50 mM metformin laid significantly more eggs than untreated
controls but after 14 days of treatment, egg-laying in females on
25 mM metformin was comparable to untreated controls while
females on 50 mM laid significantly fewer eggs than untreated
controls. Females on 100 mM metformin laid significantly fewer
eggs than untreated controls at all time points. No delay in
reproduction was observed for any concentration of metformin
used (Figure 3A).
It is possible that the increased egg-laying observed for females
treated with 25 mM and 50 mM metformin may contribute to
their decreased survival because reproduction and somatic
maintenance may compete for nutritional resources [35]. To test
this, we maintained females in the absence of metformin until they
had reached a post-reproductive age (39 days) and then switched
them onto food containing 0 mM, 25 mM or 50 mM metformin
and monitored their survival. We found that even in the absence of
egg-laying, feeding flies with either 25 mM or 50 mM metformin
decreased their survival (Figure 3B).
Metformin Induces a Dose-Dependent Reduction in Fat
Stores
In mammals, activation of AMPK by metformin induces fatty
acid oxidation and inhibits lipogenesis, reducing the levels of
stored lipids. Lipid stores are also decreased in worms raised in the
Figure 2. Metformin does not increase lifespan in Drosophila. A. Survival curves of wild-type (Dahomey) males and females maintained on
food containing no metformin or final concentrations of 1 mM, 2.5 mM or 5 mM metformin. No significant differences in survival were observed
between metformin treated flies and non-treated controls by the Log-rank test. For males, median survival times on 0 mM, 1 mM, 2.5 mM and 5 mM
metformin were 57 (n = 96), 59 (n = 96), 55 (n = 97) and 57 (n = 96) days, respectively. For females, median survival times were 67 days for all
conditions (0 mM n=96, 1 mM n=96, 2.5 mM n=99 and 5 mM n=91). B. Survival curves of wild-type (Dahomey) males and females maintained on
food containing no metformin or final concentrations of 5 mM, 10 mM, 25 mM, 50 mM or 100 mM metformin. The survival curves for males
maintained on 0 mM, 5 mM, 10 mM, 25 mM and 50 mM are not significantly different, while males maintained on 100 mM metformin were
significantly shorter lived than non-treated controls (P,0.0001 by the Log-rank test). Median survival times for males on 0 mM, 5 mM, 10 mM,
25 mM, 50 mM and 100 mM metformin were 54 (n = 97), 58 (n = 91), 51 (n = 93), 51 (n = 93), 51 (n = 98) and 37 (n = 99) days, respectively. The survival
curves for females maintained on 0 mM, 5 mM and 10 mM metformin are not significantly different. Females maintained on 25 mM, 50 mM and
100 mM metformin were significantly shorter lived than non-treated controls (P,0.001 by the Log-rank test). Median survival times for females on
0 mM, 5 mM, 10 mM, 25 mM, 50 mM and 100 mM metformin were 65 (n = 96), 65 (n = 100), 63 (n = 98), 58 (n = 101), 51 (n = 91) and 22 (n = 99) days
respectively.
doi:10.1371/journal.pone.0047699.g002
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presence of metformin [20]. In Drosophila, lipids are primarily
stored as triaceylglycerides (TAGs) in the fat body and after 7 days
of treatment, TAG levels were significantly reduced in females fed
with 10 mM or 100 mM metformin compared to untreated
controls (Figure 4A). Thus, metformin also has dose-dependent
effects on fat metabolism in Drosophila.
Metformin Treatment Disrupts Intestinal Fluid
Homeostasis
A common side-effect of metformin treatment in diabetic
patients is gastrointestinal upset. We therefore used a recently
developed assay to examine the effects of metformin on intestinal
physiology in Drosophila by examining fly excreta [36]. After 7 days
of treatment with 0 mM, 1 mM, 10 mM and 100 mM metformin,
Bromophenol blue was added to the food and then the resulting
coloured excreta were collected for 24 hours. There were no
obvious differences in the number or size of excreta deposits
between metformin treated flies and untreated controls (Figure 4B
and 4C). However, the intensity of the Bromophenol blue dye
within the deposits of flies treated with 100 mM metformin was
significantly higher than untreated controls (Figure 4D) suggesting
that the faecal output of these flies is more concentrated. In
addition, flies fed with 100 mM metformin excrete a greater
proportion of concentrated oblong deposits called RODS or
reproductive oblong deposits [36] (Figure 4E). These data suggest
that treatment with high concentrations of metformin lead to fluid
imbalances in the fly intestine resulting in the production of more
concentrated faecal deposits.
Discussion
In this study, we have examined whether the biguanide drug,
metformin, functions as a dietary restriction (DR)-mimetic in
Drosophila. In flies, DR is usually induced by dilution of dietary
yeast while maintaining constant dietary sucrose [37,38]. Under
these conditions, DR increases both median and maximum
lifespan and, in females, reduces fecundity [37,38]. Despite testing
a wide range of concentrations, we did not observe any beneficial
effects of metformin treatment on lifespan in either male of female
flies. Instead, metformin reduced survival in Drosophila in a dose-
dependent manner. Our results are consistent with a previous
study which also found no statistically significant effect of
metformin treatment on mortality rate in Drosophila although only
one concentration of metformin was used and the efficacy of this
metformin dose was not tested [39]. We also saw no reduction in
female egg-laying except at the most toxic dose, and at
intermediate concentrations, metformin actually increased egg-
laying at least at young ages. This increase in egg-laying was not,
however, responsible for the observed decrease in survival because
metformin still decreased survival when administered at post-
reproductive ages.
Mass spectrometric analysis of metformin concentration in fly
tissues confirmed that the drug was readily absorbed from the gut
and we observed robust activation of the fly AMPK, a downstream
target which is activated by metformin treatment in mammals and
is required for several of its metabolic effects [21]. In worms,
metformin-induced lifespan extension requires the activity of
AMPK and its upstream activating kinase, LKB1 [20]. However,
we have shown in this study that AMPK activation by metformin
was not sufficient to extend lifespan in flies. AMPK is not the only
downstream target of metformin. For example, metformin inhibits
the target of rapamycin (TOR) kinase independently of AMPK in
Drosophila [40]. It is therefore possible that metformin has
deleterious AMPK-independent effects in flies that mask any
beneficial effects of AMPK activation on lifespan. Hence, we
cannot exclude the possibility that AMPK activation via alterna-
tive mechanisms may increase lifespan in flies. For example, recent
evidence suggests that over-expression of the AMPK-activating
kinase, LKB1, increases survival in Drosophila [30], although
whether this effect is dependent on increased AMPK activity has
yet to be ascertained.
Although the beneficial effects of metformin on lifespan do not
appear to be evolutionarily conserved in Drosophila, we did observe
conserved effects on fat metabolism in flies. In worms, metformin
treatment is associated with reduced fat stores [20]. Similarly, in
mammals metformin induces fatty acid oxidation and inhibits
lipogenesis thereby reducing lipid stores [10,41]. In Drosophila
lipids are primarily stored as triaceylglycerides (TAGs) in the fat
body, the insect equivalent of the mammalian liver and white
adipose tissue. We have shown that metformin reduces TAG levels
and interestingly, this reduction in lipid stores was observed at
Figure 3. Effects of metformin on female egg-laying and post-
reproductive survival. (A) Egg-laying profiles of wild-type females
treated with 0 mM, 5 mM, 10 mM, 25 mM, 50 mM and 100 mM
metformin. Eggs were counted from 10 vials per treatment (10 females
per vial) over a 24 hour period after 7, 14 and 21 days of metformin
treatment. Data are shown as means 6SEM. * denotes statistically
significant difference (P,0.05). No significant differences were observed
in egg-laying between females on 0 mM, 5 mM and 10 mM metformin
at any time point. After 7 days of treatment, females on 25 mM and
50 mM metformin laid significantly more eggs than untreated controls.
After 14 days of treatment, females on 50 mM laid significantly fewer
eggs than untreated controls. Females on 100 mM metformin laid
significantly fewer eggs than untreated controls at all time points. (B)
Survival curves for post-reproductive wild-type females maintained on
food containing no metformin or final concentrations 25 mM and
50 mM metformin. Flies (n = 250 for each concentration) were switched
onto food containing metformin at 39 days of age (red arrow). Females
maintained on 25 mM or 50 mM showed reduced survival compared to
flies maintained in the absence of metformin (P,0.001 by the Log-rank
test).
doi:10.1371/journal.pone.0047699.g003
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a non-toxic concentration of metformin at which both survival and
female egg-laying were unaffected. It is therefore possible to triage
the metabolic effects of metformin on fat metabolism from its
deleterious effects on survival by simply reducing the dosage.
The minimum dose of metformin used in our experiments was
1 mM and this concentration produced no obvious physiological
effects. For example, survival, female egg-laying, TAG levels and
intestinal physiology in flies treated with 1 mM metformin were all
comparable to untreated controls. Furthermore, AMPK activation
is only apparent at doses above 5 mM. It is therefore unlikely that
the optimal metformin dose for lifespan is lower than that tested.
The toxic effects of high concentrations of metformin in
Drosophila could be mediated via several mechanisms. In C. elegans,
metformin treatment at doses that extended lifespan in wild-type
worms was found to be deleterious in combination with the eat-2
mutation, possibly as a result of excessive metabolic down-
regulation and induction of a starvation-like phenotype [20]. High
levels of AMPK activity in metformin-treated flies may similarly
reduce metabolic rates to such an extent as to induce analogous
starvation-like phenotypes resulting in reduced survival and
decreased egg-production. Flies exposed to high doses of
metformin also showed several features of intestinal fluid
imbalance including the production of more concentrated excreta,
used as a method to preserve water in insects [36]. Interestingly, in
several Drosophila species lowered levels of lipogenic stores correlate
with reduced tolerance to desiccation [42]. The loss of lipid stores
observed with high doses of metformin may therefore make flies
more susceptible to fluid loss thereby decreasing their survival. At
intermediate metformin concentrations we still observed a decrease
in survival but without an associated decrease in egg production
and so in these flies, mechanisms other than starvation or fluid
imbalance must mediate metformin toxicity. In humans, the most
potentially serious side-effect of metformin treatment is lactic
acidosis [43] and so it is possible that acidosis in Drosophila
contributes to the reduced survival of metformin treated flies.
Dietary restriction remains the most public intervention that
can extend lifespan. Studies from model organisms have impli-
cated several genetic pathways that regulate the DR response
including the TOR pathway [44,45] and insulin/insulin-like
growth factor signalling [46,47,48] yet the precise molecular
Figure 4. Metformin reduces lipid stores and causes intestinal fluid imbalance. (A) Quantitation of triacylglycerides (TAGs) in flies treated
with 0 mM, 1 mM, 10 mM and 100 mM metformin for 7 days. TAG levels decrease with increasing metformin concentration with significantly lower
levels in the 10 mM and 100 mMmetformin groups compared to untreated controls (P,0.05, n = 10 (2 flies per replicate)). (B) Metformin treatment of
female flies does not affect the number of fecal deposits produced per fly over a 24 hour period (P.0.05, Wilcoxen test, n = 5 (5 flies per replicate)).
(C) Metformin treatment of female flies does not affect the size of fecal deposits as measured by the mean area of deposits (P.0.05, Wilcoxen test,
n = 5 (5 flies per replicate)). (D) Female flies fed with 100 mM metformin produce more concentrated fecal deposits as measured by increased
average dye intensity (P,0.05, Wilcoxen test, n = 5 (5 flies per replicate)). (E) Female flies fed with 100 mM metformin produce more RODs as
a percentage of their total excreta output (P,0.05, Wilcoxen test, n = 5 (5 flies per replicate)).
doi:10.1371/journal.pone.0047699.g004
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mechanisms whereby DR promotes survival remain elusive. It is
also unclear whether the effects of DR on lifespan in different
organisms are mediated via the same mechanism or have arisen as
a result of convergent evolution. Pharmacological interventions
that mimic the effects of DR in one model organism may therefore
prove ineffectual in another. Our data would suggest that while
metformin appears to function as a DR-mimetic in worms, its
beneficial effects on survival do not translate across to Drosophila. In
mammals, the effects of metformin on lifespan are yet to be tested
in a long-lived outbred strain, using a range of concentrations,
preferably alongside a DR group, and with sufficient data on food
intake and body weight to exclude possible DR effects (reviewed in
[49]). Therefore, the extent to which metformin functions as a DR-
mimetic to benefit mammalian and importantly human lifespan
remains to be seen.
Materials and Methods
Drosophila Culture
The wild-type stock Dahomey was collected in 1970 in Dahomey
(now Benin) and has since been maintained in large population
cages with overlapping generations on a 12L:12D cycle at 25uC.
Dahomey is positive for the endosymbiont, Wolbachia pipientis. Stocks
were maintained and all experiments were conducted at 25uC on
a 12 h:12 h light:dark cycle at constant humidity using standard
sugar/yeast/agar (SYA) medium [38]. For all experiments, flies
were reared at standard larval density and eclosing adults were
collected over a 12 hour period. Flies were mated for 48 hours
before sorting into single sexes.
Metformin Treatment
Metformin (Sigma) was added directly to SYA food from a 1M
aqueous stock to give final concentrations of 1, 2.5, 5, 10, 25, 50
and 100 mM. For control food (0 mM) water alone was added.
Lifespan Assays
For lifespan experiments, flies were maintained in vials at
a density of 10 flies per vial on standard SYA medium. Flies were
transferred to new vials three times per week and the number of
deaths counted.
Female Fecundity Assays
Female flies were housed with males for 48 hours post-eclosion
and then separated into vials at a density of 10 females per vial.
Eggs were collected over two 24-hour periods per week for 4
weeks. The number of eggs laid per vial at each time point was
counted.
Western Blotting
40 mg of total protein were resolved on 10% Tris-Glycine-SDS
gels. Proteins were transferred to nitrocellulose membranes and
probed for phospho-Thr172-AMPK (1:1000; Cell Signaling) and
actin (1:5000; Sigma). Secondary antibodies conjugated to HRP
were purchased from Biorad.
Triacylglyceride (TAG) Measurements
Flies were homogenised in 0.05% Tween-20 and TAG levels
were measured using the Triglyceride Infinity Reagent (Thermo-
Scientific) and triglyceride standards. TAG levels were normalised
to body weight.
Mass Spectrometric Determination of Metformin
Concentration in Flies
Flies were homogenised in phosphate buffered saline and all
samples were spiked with 7.3 nM phenformin (Sigma) as an
internal standard. For the standard curve, non-treated flies were
homogenised and then samples spiked with metformin resulting in
final concentrations of 5–80 ng/ml. Proteins were precipitated by
the addition of acetonitrile. Mass spectrometric analysis of
metformin concentration was performed by Dr Carolyn Hyde of
the Scientific Support Services, Wolfson Institute for Biomedical
Research, University College London using Shimadzu LC-MS-
ITToF.
Fly Defecation Assay
Analysis of fly excreta was performed according to [36]. Fly
food was supplemented with 0.5% Bromophenol blue sodium salt
(B5525, Sigma). Analyses of excreta (including number, shape, size
and dye intensity) were carried out on 25 flies housed in 50 mm
Petri dishes (5 flies per dish). Digital images of Petri dishes were
obtained using an Epson Perfection 4990 Photo scanner and
whole-image background adjustments were applied using Adobe
Photoshop. Digital scans were analysed using Volocity 64 software
(Improvision) using the protocols described in [36]. Colour (Mean
Red, Mean Green and Mean Blue) and size (Pixel Count and
Perimeter) values were exported to the R environment (R
Development Core Team, 2009) and converted to Hue, Satura-
tion, Lightness values. Dye intensity was calculated as 100 2
lightness.
Statistical Analyses
Statistical analyses were performed using JMP software (version
9.0; SAS Institute). Log rank tests were performed on survival
curves. Other data were tested for normality using the Shapiro-
Wilk W test on studentised residuals and where appropriate log-
transformed. One-way analyses of variance (ANOVA) and
planned comparisons of means were made using Tukey-Kramer
HSD test.
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